Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Executive VP, Discovery Research, Jan Lundberg: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

AstraZeneca's chief of discovery research discusses his company's pipeline, its plans related to the acquisitions of MedImmune and CAT, and whether the Exanta compound has any developmental future with "The Pink Sheet" DAILY.

You may also be interested in...



Two More Phase III Zactima Trials Reach Full Enrollment

AstraZeneca’s investigational drug for non-small cell lung cancer remains on track for an NDA filing this year.

Two More Phase III Zactima Trials Reach Full Enrollment

AstraZeneca’s investigational drug for non-small cell lung cancer remains on track for an NDA filing this year.

AstraZeneca Executive VP, Discovery Research, Jan Lundberg, An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Exec addresses oncology pipeline, Bristol diabetes deal.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel